J1I-MC-GZBU - A Phase 2b, Double-Blind Study to Investigate the Effect of LY3437943 on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504583-42-00

Acronym

J1I-MC-GZBU

Enrollment

Registered

2023-11-14

Start date

2024-05-07

Completion date

2025-09-17

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Brief summary

Change in GFR (mL/min/m2 ) using iohexol clearance

Interventions

DRUGIOHEXOL

DRUGPlacebo to match LY3437943

DRUGRetatrutide

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in GFR (mL/min/m2 ) using iohexol clearance	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026

J1I-MC-GZBU​ - A Phase 2b, Double-Blind Study to Investigate the Effect of LY3437943 on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes